Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25.

2.

Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis.

Touil H, Kobert A, Lebeurrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J, Antel JP, Itoyama Y, Nakashima I, Bar-Or A; Canadian B Cell Team in MS.

J Neuroinflammation. 2018 Apr 19;15(1):114. doi: 10.1186/s12974-018-1136-2.

3.

The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Li R, Bar-Or A.

Cold Spring Harb Perspect Med. 2018 Apr 16. pii: a029108. doi: 10.1101/cshperspect.a029108. [Epub ahead of print]

PMID:
29661809
4.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
5.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

6.

The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.

Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, Arnold D, O'Mahony J, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089. [Epub ahead of print]

PMID:
29393768
7.

MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS.

Healy LM, Jang JH, Won SY, Lin YH, Touil H, Aljarallah S, Bar-Or A, Antel JP.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 16;4(6):e402. doi: 10.1212/NXI.0000000000000402. eCollection 2017 Nov.

8.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343. [Epub ahead of print]

PMID:
28911260
9.

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.

Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, Giacomini PS, Bar-Or A, Antel J.

Mult Scler. 2017 Aug;23(9):1225-1232. doi: 10.1177/1352458517713147.

PMID:
28749311
10.

B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.

Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, Touil H, Li R, Muirhead G, Bar-Or A.

J Neuroimmunol. 2017 Aug 15;309:88-99. doi: 10.1016/j.jneuroim.2017.05.004. Epub 2017 May 17.

PMID:
28601295
11.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
12.

Monophasic demyelination reduces brain growth in children.

Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2017 May 2;88(18):1744-1750. doi: 10.1212/WNL.0000000000003884. Epub 2017 Apr 5.

13.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
14.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

15.

White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.

Longoni G, Brown RA, MomayyezSiahkal P, Elliott C, Narayanan S, Bar-Or A, Marrie RA, Yeh EA, Filippi M, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Network.

Brain. 2017 May 1;140(5):1300-1315. doi: 10.1093/brain/awx041.

PMID:
28334875
16.

Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.

Li R, Rezk A, Li H, Gommerman JL, Prat A, Bar-Or A; Canadian B Cells in MS Team.

J Immunol. 2017 Apr 15;198(8):3245-3254. doi: 10.4049/jimmunol.1601572. Epub 2017 Mar 8.

17.

Cyberinfrastructure for Open Science at the Montreal Neurological Institute.

Das S, Glatard T, Rogers C, Saigle J, Paiva S, MacIntyre L, Safi-Harab M, Rousseau ME, Stirling J, Khalili-Mahani N, MacFarlane D, Kostopoulos P, Rioux P, Madjar C, Lecours-Boucher X, Vanamala S, Adalat R, Mohaddes Z, Fonov VS, Milot S, Leppert I, Degroot C, Durcan TM, Campbell T, Moreau J, Dagher A, Collins DL, Karamchandani J, Bar-Or A, Fon EA, Hoge R, Baillet S, Rouleau G, Evans AC.

Front Neuroinform. 2017 Jan 6;10:53. doi: 10.3389/fninf.2016.00053. eCollection 2016.

18.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

19.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

20.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.

21.

Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.

Kaushik DK, Yong HY, Hahn JN, Silva C, Casha S, Hurlbert RJ, Jacques FH, Lisak R, Khan O, Ionete C, Larochelle C, Prat A, Bar-Or A, Yong VW.

PLoS One. 2016 Oct 11;11(10):e0163802. doi: 10.1371/journal.pone.0163802. eCollection 2016.

22.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

23.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

24.

Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases.

Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T.

Neurology. 2016 Aug 30;87(9 Suppl 2):S12-9. doi: 10.1212/WNL.0000000000002821. Review.

PMID:
27572856
25.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.

Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.

PMID:
27543447
26.

Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.

Bühler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C, Gollan R, Wolf C, Lutz J, Bar-Or A, Siffrin V, Zipp F.

Mult Scler. 2017 Apr;23(4):567-576. doi: 10.1177/1352458516658559. Epub 2016 Jul 21.

PMID:
27436357
27.

Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A.

Stem Cells Transl Med. 2016 Nov;5(11):1506-1514. doi: 10.5966/sctm.2015-0243. Epub 2016 Jul 11.

28.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS.

Lancet. 2016 Aug 6;388(10044):576-85. doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9.

PMID:
27291994
29.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

30.

Differential transcriptional response profiles in human myeloid cell populations.

Healy LM, Perron G, Won SY, Rao VTS, Guiot MC, Moore C, Bar-Or A, Antel JP.

Clin Immunol. 2018 Apr;189:63-74. doi: 10.1016/j.clim.2016.04.006. Epub 2016 Apr 16.

PMID:
27094466
31.

Central nervous system inflammation across the age span.

Bar-Or A, Antel JP.

Curr Opin Neurol. 2016 Jun;29(3):381-7. doi: 10.1097/WCO.0000000000000331. Review.

PMID:
27035901
32.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

33.

MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells.

Healy LM, Perron G, Won SY, Michell-Robinson MA, Rezk A, Ludwin SK, Moore CS, Hall JA, Bar-Or A, Antel JP.

J Immunol. 2016 Apr 15;196(8):3375-84. doi: 10.4049/jimmunol.1502562. Epub 2016 Mar 9.

34.

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A.

Mult Scler J Exp Transl Clin. 2016 Feb 19;2:2055217316634111. doi: 10.1177/2055217316634111. eCollection 2016 Jan-Dec.

35.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.

Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.

PMID:
26879276
36.

MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age.

Rao VT, Ludwin SK, Fuh SC, Sawaya R, Moore CS, Ho MK, Bedell BJ, Sarnat HB, Bar-Or A, Antel JP.

J Neuropathol Exp Neurol. 2016 Feb;75(2):156-66.

PMID:
26802178
37.

Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity.

Pikor NB, Prat A, Bar-Or A, Gommerman JL.

Front Immunol. 2016 Jan 13;6:657. doi: 10.3389/fimmu.2015.00657. eCollection 2015. Review.

38.

Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.

Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle AM, Giacomini PS, Bar-Or A, Antel JP.

Ann Clin Transl Neurol. 2015 Dec 2;3(1):27-41. doi: 10.1002/acn3.270. eCollection 2016 Jan.

39.

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.

Li R, Rezk A, Healy LM, Muirhead G, Prat A, Gommerman JL, Bar-Or A; MSSRF Canadian B cells in MS Team.

Front Immunol. 2016 Jan 8;6:626. doi: 10.3389/fimmu.2015.00626. eCollection 2015. Review.

40.

B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation.

Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A.

Front Immunol. 2015 Dec 24;6:636. doi: 10.3389/fimmu.2015.00636. eCollection 2015. Review.

41.

Multiple sclerosis and related disorders: evolving pathophysiologic insights.

Bar-Or A.

Lancet Neurol. 2016 Jan;15(1):9-11. doi: 10.1016/S1474-4422(15)00342-7. Epub 2015 Dec 8. Review. No abstract available.

PMID:
26700897
42.

Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.

Lino AC, Dörner T, Bar-Or A, Fillatreau S.

Immunol Rev. 2016 Jan;269(1):130-44. doi: 10.1111/imr.12374. Review.

PMID:
26683150
43.

Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.

Pikor NB, Astarita JL, Summers-Deluca L, Galicia G, Qu J, Ward LA, Armstrong S, Dominguez CX, Malhotra D, Heiden B, Kay R, Castanov V, Touil H, Boon L, O'Connor P, Bar-Or A, Prat A, Ramaglia V, Ludwin S, Turley SJ, Gommerman JL.

Immunity. 2015 Dec 15;43(6):1160-73. doi: 10.1016/j.immuni.2015.11.010.

44.

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.

Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser MT, Kurukulasuriya N, Viglietta V, Fox RJ.

Neurol Ther. 2015 Dec;4(2):93-104. doi: 10.1007/s40120-015-0033-1. Epub 2015 Oct 12.

45.

Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation.

Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G, Tacke R, Basat AB, Mikulski Z, Togher S, Miller J, Blatchley A, Salek-Ardakani S, Darvas M, Kaikkonen MU, Thomas GD, Lai-Wing-Sun S, Rezk A, Bar-Or A, Glass CK, Bandukwala H, Hedrick CC.

Nat Immunol. 2015 Dec;16(12):1228-34. doi: 10.1038/ni.3321. Epub 2015 Nov 2.

46.

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A; Canadian B cells in MS Team.

Sci Transl Med. 2015 Oct 21;7(310):310ra166. doi: 10.1126/scitranslmed.aab4176.

PMID:
26491076
47.

Sequencing the immunopathologic heterogeneity in multiple sclerosis.

Antel JP, Ludwin SK, Bar-Or A.

Ann Clin Transl Neurol. 2015 Sep;2(9):873-4. doi: 10.1002/acn3.230. No abstract available.

48.

Neuroinflammation: Ways in Which the Immune System Affects the Brain.

Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A.

Neurotherapeutics. 2015 Oct;12(4):896-909. doi: 10.1007/s13311-015-0385-3. Review.

49.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

50.

Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.

Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2016 Mar;22(3):385-8. doi: 10.1177/1352458515595876. Epub 2015 Jul 21.

PMID:
26199356

Supplemental Content

Loading ...
Support Center